LOGO.png
Autolus Therapeutics to host Investor Conference Calls through June
May 26, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
May 22, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
LOGO.png
Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting
May 15, 2020 11:20 ET | Autolus Therapeutics plc
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25,...
LOGO.png
Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting
May 15, 2020 07:00 ET | Autolus Therapeutics plc
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held...
LOGO.png
Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
May 14, 2020 07:00 ET | Autolus Therapeutics plc
- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30...
LOGO.png
Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress
May 07, 2020 07:00 ET | Autolus Therapeutics plc
- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company...
LOGO.png
Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7
May 01, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia
April 16, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
LOGO.png
Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress
March 03, 2020 07:07 ET | Autolus Therapeutics plc
- Conference call to be held on March 3, 2020 at 8:30 am EST/1:30 pm GMT - LONDON, March 03, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical...
LOGO.png
Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference
February 25, 2020 07:00 ET | Autolus Therapeutics plc
LONDON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...